PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: COPD: An overview • Causes and risk factors • Symptoms • Diagnosis • Management PART 06: China-Country snapshot • Social and economic conditions • Healthcare reform • Healthcare infrastructure PART 07: Pharmaceutical industry in China • Market overview • Major pharmaceutical vendors in China • Opportunities for global and local vendors • Drug approval process in China PART 08: Drug pricing and reimbursement • Market-driven drug pricing strategy • Scrutinization of illegal pricing of drugs PART 09: Pipeline portfolio PART 10: Global respiratory drugs market • Market overview • Global COPD drugs market PART 11: Market landscape • COPD drugs market in china • Five forces analysis PART 12: Market segmentation by drug class • Bronchodilators • PDE-4 inhibitors • Steroids • Combination therapies • Other medications PART 13: Market drivers • Increase in prevalence of smoking • Rise in healthcare expenditure • Increase in environmental pollution PART 14: Impact of drivers PART 15: Market challenges • Low diagnosis rate • Alternative therapies • High cost of therapy PART 16: Impact of drivers and challenges PART 17: Market trends • Rise in awareness programs • Increased focus on combination therapies • Rise in R&D by global companies PART 18: Vendor landscape • Competitive scenario • AstraZeneca • Boehringer Ingelheim • GSK • Merck • Novartis • Other prominent vendors PART 19: Appendix • List of abbreviations PART 20: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: China GDP 2010-2014 ($ trillions) Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP) Exhibit 04: Healthcare reforms in China Exhibit 05: Pharmaceutical market in China 2015-2020 ($ billions) Exhibit 06: Some top domestic and international vendors operating in China Exhibit 07: China pharmaceutical market overview: SWOT analysis Exhibit 08: New drug approval (NDA) review process in China Exhibit 09: New drug approval process in China Exhibit 10: Drug registration classification and requirements in China Exhibit 11: Changes in drug pricing system before and after 2015 reforms Exhibit 12: Pipeline portfolio: COPD drugs Exhibit 13: Global respiratory drugs market 2015-2020 ($ billions) Exhibit 14: Global respiratory drugs market shares by type of disease 2015 Exhibit 15: Global COPD drugs market 2015-2020 ($ billions) Exhibit 16: Key drivers and challenges in global COPD drugs market Exhibit 17: Global COPD drugs market by class of drugs 2015 Exhibit 18: COPD drugs in China in global respiratory drugs market 2015 Exhibit 19: COPD drugs market in China 2015-2020 ($ billions) Exhibit 20: Five forces analysis Exhibit 21: Segmentation of COPD drugs based on drug class Exhibit 22: Healthcare spending in China 2004-2014 Exhibit 23: Impact of drivers Exhibit 24: Impact of drivers and challenges Exhibit 25: AstraZeneca: YoY revenue and growth rate of Symbicort in China 2014-2015 ($ millions) Exhibit 26: AstraZeneca: YoY revenue and growth rate of Symbicort in emerging markets 2013-2015 ($ millions) Exhibit 27: AstraZeneca: YoY revenue and growth rate of Pulmicort in China 2014-2015 ($ millions) Exhibit 28: AstraZeneca: YoY revenue and growth rate of Pulmicort in emerging markets 2013-2015 ($ millions) Exhibit 29: AstraZeneca: Key takeaways Exhibit 30: Boehringer Ingelheim: Key takeaways Exhibit 31: GSK: YoY revenue and growth rate of Seretide/Advair in international markets 2014-2015 ($ billions) Exhibit 32: GSK: YoY revenue and growth rate of Flixotide/Flovent in international markets 2014-2015 ($ millions) Exhibit 33: GSK: YoY revenue and growth rate of Ventolin in international markets 2014-2015 ($ millions) Exhibit 34: GSK: YoY growth and revenue of Relvar/Breo Ellipta in international markets 2014-2015 ($ millions) Exhibit 35: GSK: Key takeaways Exhibit 36: Merck: Key takeaways Exhibit 37: Novartis: Key takeaways

AstraZeneca, Boehringer Ingelheim, GSK, Merck, Novartis, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab.